Growing evidence implicates the importance of glia, particularly astrocytes, in neurological and psychiatric diseases. Here, we describe a rapid and robust method for the differentiation of highly pure populations of replicative astrocytes from human induced pluripotent stem cells (hiPSCs), via a neural progenitor cell (NPC) intermediate. Using this method, we generated hiPSC-derived astrocyte populations (hiPSC-astrocytes) from 42 NPC lines (derived from 30 individuals) with an average of ~90% S100β-positive cells. Transcriptomic analysis demonstrated that the hiPSC-astrocytes are highly similar to primary human fetal astrocytes and characteristic of a non-reactive state. hiPSC-astrocytes respond to inflammatory stimulants, display phagocytic capacity and enhance microglial phagocytosis. hiPSC-astrocytes also possess spontaneous calcium transient activity. Our novel protocol is a reproducible, straightforward (single media) and rapid (<30 days) method to generate homogenous populations of hiPSC-astrocytes that can be used for neuron-astrocyte and microglia-astrocyte co-cultures for the study of neuropsychiatric disorders.
INTRODUCTION
existing methods are slow (up to six months) 17, 22, 23 and/or require sorting to reduce heterogeneity 25, 26 . Here, we screened a number of published protocols, along with commercially available media for primary human astrocyte culture, identifying a robust and straightforward differentiation protocol for generating highly pure astrocytes from hiPSCs. By co-culture with microglia, we compared the function of primary human fetal astrocytes and hiPSC-astrocytes in assays for neuroinflammatory response, phagocytosis, and spontaneous calcium activity, concluding that hiPSC-astrocytes are highly similar to their primary counterparts. Altogether, our rapid differentiation protocol, co-culture strategy and scalable phenotypic assays will serve as a robust platform for queries of healthy and diseased human astrocytes.
RESULTS

30-day exposure of hiPSC-derived NPCs to commercial astrocyte media is sufficient to robustly generate hiPSC-astrocytes
We first screened 11 different media conditions on forebrain-patterned NPCs 27,28 derived from hiPSCs ( Table 1 ). The screening conditions included different combinations of fibroblast growth factor 2 (FGF2) 20 , ciliary neurotrophic factor (CNTF) 17, 22 , bone morphogenetic protein 4 (BMP4) 22, 23, 29 , fibroblast bovine serum (FBS) 22, 29 , neuregulin 22, 30 , insulin 31 and ascorbic acid (AA) 32 , as well as three commercial astrocyte media (ScienCell, Gibco, and Lonza) for the culture of primary human fetal astrocytes ( Table 1) . Screening criteria included immunoreactivity for two classical markers of astrocyte identity, S100β and GFAP 33 , astrocyte morphology, survival, and cell line variability ( Supplementary Table 1 ; Supplementary   Fig.1a ). While other conditions resulted in cell line variation, limited cell proliferation, and expression of neuronal markers (Supplementary Table 1) , two commercial media, ScienCell and Lonza, yielded the most S100β-and GFAP-positive astrocyte-like cells ( Supplementary  Fig.1b-d) . These results were confirmed across four representative NPC lines both by flow cytometry and immunocytochemistry by 30 days ( Fig. 1a; Supplementary Fig.1e-g) . Culture of NPCs in both media, when combined with low initial seeding density (nearly single cells: 15,000 cells/cm 2 ) and minimal serum exposure (1-2%), resulted in astrocyte morphology within ten days ( Supplementary Fig.1h ); star-shaped astrocyte morphologies were evident within 30 days ( Supplementary Fig.1i ). Although ScienCell and Lonza astrocyte media showed equivalent efficiencies ( Supplementary Fig.1b-d) , ScienCell medium was selected owing to its lower cost and relative simplicity.
We next tested the efficacy of this protocol across 42 NPC lines from 30 individuals (16 male and 14 female) generated as part of three unique hiPSC cohorts (reprogrammed and differentiated through different protocols in independent laboratories) ( Table 2; Supplementary   Table 2 ). All 42 NPC lines ultimately yielded hiPSC-astrocytes (although not necessarily on the first attempt), with an average composition of 90% S100β+ and 82% GFAP+ cells by flow cytometry (Fig.1b) , and confirmed by immunocytochemistry, although GFAP intensity was highly variable (Fig. 1a,c; Supplementary Fig.1j-k) . Within 30 days, hiPSC-astrocytes were also immuno-positive for the astrocyte markers ALDH1L1 34 and Vimentin (VIM) 35 , as well as the glutamate transporters GLAST (EAAT1) 36 (Fig. 1c; Supplementary Fig. 1l-m ). Compared to NPCs or excitatory neurons (hNGN2-induced neurons) 37 , hiPSC-astrocytes expressed high levels of GFAP 33 , S100β 33 , VIM 35 , AQU4 38 , ACSBG1 25 and APOE 39 by qPCR ( Fig. 1d ). In addition, hiPSC-astrocytes expressed low levels of the neuronal markers TUJ1, MAP2AB, RELN, and CACNA1C (Fig. 1e) . Table 4 ) in 23 hiPSCastrocyte lines and their isogenic NPC lines, principal component analysis (PCA) revealed that the NPCs grouped together, while the astrocytes (both hiPSC-derived and primary human fetal astrocytes) were more dispersed ( Fig. 1f; Supplementary Fig. 1n ). Because it was apparent in our hiPSC-astrocytes as well as the primary human fetal astrocytes (obtained from different donors and brain regions), this variability in lineage marker expression may reflect interindividual variability and/or differences in regional patterning ( Fig. 1g; Supplementary Fig. 1o ).
Across a larger panel of neural lineage markers (Supplementary
hiPSC-astrocytes and primary human fetal astrocytes share similar transcriptional profiles
To query the extent to which global gene expression in hiPSC-astrocytes resembles primary human fetal brain astrocytes, we performed transcriptomic analyses (RNAseq) on hiPSCastrocytes and primary human fetal astrocytes from two brain regions (cerebral cortex and midbrain), together with isogenic hiPSC-derived NPCs and neurons ( Fig. 2; Supplementary   Fig. 2 ), comparing them to in vivo human and rodent astrocyte transcriptomic datasets (Figs. 2-3; Supplementary Figs. 2-3 ). hiPSC-astrocytes showed transcriptional profiles most similar to fetal brain astrocytes. Using principal component analysis and hierarchical clustering, all four hiPSC-astrocytes clustered together with the primary human fetal astrocytes and distinct from the NPC and neuron clusters ( Fig. 2a-b ; Supplementary Fig. 2a ).
There were nearly six-fold fewer differentially expressed genes (DEGs) between hiPSCastrocytes and primary human fetal astrocytes (900 genes) than between hiPSC-astrocytes and isogenic hiPSC-derived neurons (10,000 genes) or NPCs (5500 genes) ( Fig. 2c ; Supplementary Fig. 2b ). hiPSC-astrocytes are highly similar to primary human fetal astrocytes (r = 0.945); the majority of both expressed genes (counts per million (CPM) > 1) and enriched genes (counts per million (CPM) > 5) were shared between hiPSC-astrocytes and primary human fetal astrocytes (87.0 and 90.3%, respectively) ( Fig. 2d) . Functional enrichment analyses (using MSigDB) demonstrated that signals regulating neuronal maturation, such as synapse or ion channel formation, were downregulated in hiPSC-astrocytes and primary human fetal astrocytes, whereas signals promoting extracellular cell adhesion and interaction were upregulated ( Fig. 2e) . When we specifically considered just the top 100 most variable genes distinguishing hiPSC-derived astrocytes from NPCs and neurons, functional enrichment analysis identified a group of 19 genes related to reactivity, cytokine, interferon, T cell receptor (TCR), and antigen processing signaling that were enriched in astrocytes (G2) ( Fig. 3a ; Table 3 ; Supplementary Fig. 3a) .
To assess the extent to which hiPSC-astrocytes are closely related to human brain astrocytes in vivo, we compared expression profiles of hiPSC-derived astrocytes, NPCs, neurons, and primary human fetal astrocytes to the Allen BrainSpan: Atlas of the Developing Human Brain (http://www.brainspan.org) 40 using a Spearman Rank Correlation analysis.
Heatmaps generated through a Wilcoxon's rank-sum test revealed that gene expression in hiPSC-astrocytes and primary human fetal astrocytes was highly correlated with gene expression in human fetal cortical brain tissue (8-16 weeks post conception) ( Fig. 2f ).
Unsupervised hierarchical cell type specific cluster analysis demonstrated that hiPSC-astrocytes
closely cluster with astrocytes purified by immunopanning from human brain tissue, particularly hippocampal astrocytes, rather than oligodendrocytes, endothelial cells, myeloid cells or neurons 41 (Fig. 3a) ; pathway analysis further revealed that many astrocyte-enriched genes related to immune signaling ( Fig. 2g ).
Expression profile of hiPSC-astrocytes resembles quiescent astrocytes
To determine whether the gene expression pattern of our hiPSC-astrocytes more resembles quiescent or reactive astrocytes, we compared them to an RNAseq dataset of "proinflammatory" A1-type and "immunoregulatory" A2-type murine astrocytes, as well as their saline-and shamtreated controls 42 . (Because these are in vivo cell types, whereby A1-type astrocytes are induced by a bacterial lipopolysaccharide (LPS) infection and A2-type astrocytes by middle cerebral artery occlusion (MCAO), no comparable dataset exists for human astrocytes.) hiPSCastrocyte gene expression best clusters with the control conditions ( Fig. 3b; Supplementary   Fig. 3b ), suggesting that hiPSC-astrocytes may be closer to the quiescent state than to reactive astrocytes.
hiPSC-astrocytes secrete cytokines in response to inflammatory stimuli
A key effector of the astrocyte neuroinflammatory response in neurodegenerative diseases is interleukin 6 (IL-6) 43 . Consistent with effects observed in primary human fetal astrocytes ( Fig.   3c ), 24-hour treatment with polyinosinic-polycytidylic acid (poly(I:C)) (50 ng/ml or 100 ng/ml), LPS (10 ng/ml or 50 ng/ml), and β-amyloid 42 (Aβ42) (5 µM or 10 µM) led to dose-dependent increases in IL-6 secretion in hiPSC-astrocytes ( Fig. 3d) .
To more fully characterize the release of inflammatory mediators from hiPSC-astrocytes following 24-hour treatment with 5 µM Aβ42, a main component of the amyloid plaques in Alzheimer's Disease (AD), we measured pro-inflammatory (IL-1β, IL-4, IL-6, IL-8, IL-10, and TNFα) and anti-inflammatory cytokines (IL-1α, IL-2, IL-12, IL-17α, IFNγ, and GM-CSF) by Multi-Analyte ELISArray, confirming that Aβ42 treatment primarily increased IL-6 secretion 44 ( Supplementary Fig. 3c) , as well as a second pro-inflammatory cytokine, IL-8. We also measured 36 cytokines, chemokines and acute phase proteins using the Proteome Profiler Human Cytokine Array ( Supplementary Table 5 ) in baseline conditions and following 24-hour treatment with 5 µM Aβ42 (Supplementary Fig. 3d-f) ; Aβ42 increased IL-6 release in both hiPSC-astrocytes and primary human fetal astrocytes ( Supplementary Fig. 3d ). Together, our findings indicate that in response to neuroinflammatory cues, hiPSC-astrocytes are capable of secreting pro-inflammatory cytokines.
hiPSC-astrocytes display phagocytic capacity and promote phagocytic function of microglia
Astrocytes have been reported to phagocytose and degrade β-amyloid in AD 45, 46 . We used flow cytometry to examine the ability of hiPSC-astrocytes to phagocytose pHrodo red conjugated myelin or zymosan bioparticles (pHrodo red dye fluoresces red in the acidic environment of phagosomes; zymosan is an agonist of Toll-like receptor 2 (TLR2) 47, 48 ). hiPSC-astrocytes, primary human fetal astrocytes and BV2 microglia showed a similar capacity to internalize myelin purified from brain homogenates, while zymosan bioparticle uptake was much greater in microglia (consistent with higher levels of TLR2 reported in microglia) 49 (Fig. 4a-b ; Supplementary Fig. 4a-c; Supplementary video 1-3) . The specificity of bioparticle uptake was confirmed by treating cells with cytochalasin D, an inhibitor of β-actin polymerization that reduces phagocytosis ( Fig. 4a-b) .
Although microglia are the major phagocytic cells in the brain, astrocytes mediate microglial response to inflammatory stimuli [50] [51] [52] . We repeated the pHrodo red zymosan assay using microglia-astrocyte co-cultures; both hiPSC-astrocytes and primary human fetal astrocytes enhanced phagocytic capacity of BV2 mouse microglial cells ( Fig. 4c;   Supplementary Fig. 4d ). We discriminated microglia and astrocyte phagocytic activity by labeling CD11b-and GFAP-positive cells, respectively (Fig. 4e) . After 3 hours of labeling, only the CD11b+ BV2 microglial cells phagocytosed the pHrodo red zymosan bioparticles (Fig. 4e) Finally, we treated BV2 microglial cells with astrocyte conditioned medium (ACM) for 24-hours prior to analyzing their phagocytic capacity; pre-treatment of BV2 microglial cells with ACM from either hiPSC-astrocytes or primary human fetal astrocytes significantly increased microglial phagocytic capacity ( Fig. 4d; Supplementary Fig. 4f ). Taken together, these findings show that both hiPSC-astrocytes and primary human fetal astrocytes secrete factors that increase the capacity of microglia to phagocytose zymosan bioparticles.
hiPSC-astrocytes display spontaneous calcium transient activity
We next evaluated whether hiPSC-astrocytes exhibit spontaneous calcium transients, as has been described for astrocytes 53 . We used the calcium indicator FLUO-4AM to monitor calcium signaling under basal conditions and in response to a pulse of extracellular glutamate (3 µM) 41 .
A single pulse of glutamate produced a slow calcium response in both hiPSC-astrocytes and primary human fetal astrocytes (Fig. 5) . In addition, some cells exhibited spontaneous calcium spikes, suggesting the presence of a network of connected astrocytes 54 (Fig. 5a-d) . To quantify these responses, we measured the frequency of spontaneous activity, the number of spontaneous spikes per time, and the amplitude of the calcium spike ( Fig. 5e-g) . There was no statistical difference in the frequency and number of spikes between hiPSC-astrocytes and primary astrocytes. Interestingly, the amplitude of the spontaneous calcium spike was significantly higher in hiPSC-astrocytes compared to primary astrocytes. Taken together, the excitability of hiPSC-astrocytes was largely indistinguishable from that of primary human astrocytes.
DISCUSSION
We screened 11 methods to differentiate hiPSC-derived NPCs into astrocytes, identifying a medium with low FBS (1-2%) that produces homogenous populations of hiPSC-astrocytes within 30-days. Although this is a commercial medium sold for the culture of primary astrocytes, it has not previously been demonstrated to support differentiation of hiPSC to astrocytes. Our method is fast and robust: unlike previous reports, it does not require prolonged culture (~ 6 months) or a serial sorting process to achieve a pure population of astrocytes 17, 22, 26 . This protocol was validated across 42 NPC lines from 30 individuals (16 males and 14 females) generated from three independent hiPSC cohorts ( Table 2; Supplementary Table 2 ). We caution that the quality of the starting NPC population is a critical predictor of success and note that for a few particularly intransient NPC lines, starting from very low passage stocks proved critical to the ultimate successful differentiation of hiPSC-astrocytes. We further note that GFAP seems to be a more variable marker of astrocyte fate (Fig. 1b) and recommend instead using S100β when evaluating hiPSC-astrocyte populations. Because our protocols for NPC and astrocyte culture are robust and easily scaled, this methodology is highly amenable to automated culture and future high throughput drug screens using patient-derived astrocytes 55 .
We have established a platform for querying astrocyte-specific contributions to disease predisposition in hiPSC-based models. hiPSC-astrocytes closely resemble primary human fetal astrocytes, purified adult brain astrocytes 41 , and brain tissue homogenate 40 (Fig. 2, 3a) .
Although the transcriptional profile of our hiPSC-astrocytes most closely resembles a quiescent state (Fig. 3b) , hiPSC-astrocytes secrete various cytokines and chemokines in response to neuroinflammatory stimuli (Fig. 3c,d) . hiPSC-astrocytes displayed phagocytic capacity ( Fig. 4a) and enhanced the phagocytic function of microglia in a co-culture assay (Fig. 4d) . They also showed spontaneous calcium transient activity and responses to glutamate stimulus ( Fig. 5) .
Moreover, because nearly pure populations of excitatory neurons and astrocytes from the same individual, hiPSC clone, and even NPC batch can now be compared, our protocol may reduce experimental variation in studies of the cell autonomous and non-cell autonomous factors underlying disease predisposition.
While many studies of neurodegeneration and synaptic dysfunction use either primary mouse or human fetal glia for human neuron co-culture [56] [57] [58] , these current methods are limited by species-specific differences in astrocyte function and limited access to human fetal samples.
Our hiPSC-astrocytes overcome these drawbacks, making possible a new hiPSC-based astrocyte-neuron 59 -microglia 60,61 co-culture platform for uncovering disease-related mechanisms in vitro, which should help to reveal how the cross-talk between these three neural cell types contributes to neurological and psychiatric disease.
METHODS
Methods and any associated references are available in the online version of the paper.
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FIGURE LEGENDS
Figure 1 | Rapid differentiation of hiPSC-derived NPCs to astrocyte-like identity. (a) Representative flow cytometry analysis of S100β (top) and GFAP (bottom) for four 30-day hiPSC-astrocyte differentiations. Arrows indicate the cells positive for each marker protein. (b)
Graphs of flow cytometry analysis across 35 hiPSC-astrocyte differentiations from 26 NPC lines from three independent hiPSC cohorts. S100β (left) and GFAP (right) immunostaining is shown, with primary human fetal astrocytes (positive control) and hiPSCs (negative control). (c) Representative immunofluorescence images of hiPSC-astrocytes stained for astrocyte markers glutamate transporters GLAST (green), VIMENTIN (green), ALDH1L1 (red), and APOE (green). (d) mRNA levels of astrocyte markers: S100β, GFAP, VIM, AQU4, ACSBG1, and APOE in hiPSC-astrocytes and pAstrocytes. Primer sequences are listed in Supplementary Table 3 . (e) mRNA levels of neuronal markers: TUJ1, MAP2AB, RELN and CACNA1C in hiPSC-astrocytes and pAstrocytes, relative to hNGN2-induced neurons. Primer sequences are listed in Supplementary Table 3 . (f) Principal component analysis of lineage specific marker expression in 23 pairs of hiPSC-astrocytes and isogenic source NPCs, together with four pAstrocyte lines isolated from fetal cerebral cortex, midbrain, cerebellum and whole brain. (g) Flow cytometry analysis of S100β (top) and GFAP (bottom) for pAstrocytes from the cerebral cortex, midbrain, cerebellum and whole brain. CC: cerebral cortex, Mid: Midbrain, Cereb: Cerebellum, Mixed: whole brain. hiPSC-Astros: hiPSC-astrocytes, pAstros: primary human fetal astrocytes. Data are represented as mean ± standard deviation. A two-tailed homoscedastic Student's t-test, n.s.: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001. Fig. 2b. (d) Scatter plot (left) comparing gene expression in hiPSC-astrocytes and pAstrocytes. r represents the Spearman correlation coefficient. Venn diagram (right) of overlapping gene expression (CPM>5) between hiPSC-astrocytes and pAstrocytes. (e) Functional pathway enrichment analysis of differentially expressed genes between hiPSCastrocytes and pAstrocytes (left), hiPSC-astrocytes (middle) and NPCs, and pAstrocytes and NPCs (right); hiPSC-astrocytes and pAstrocytes express increased extracellular cell communication signals, but decreased neuronal signals relative to NPCs. (f) Heatmap produced by Wilcoxon's rank-sum comparisons of hiPSC-derived NPCs, neurons and astrocytes, as well as pAstrocytes, relative to the Allen BrainSpan Atlas. (g) Fold enrichment from functional pathway analysis of astrocyte enriched genes, group G2 sorted from top 100 most variable genes from Supplementary Fig. 3a and Table 3 . Cluster diagram of hiPSC-astrocytes and pAstrocytes compared to the astrocyte reactivity dataset 42 , which was sorted by reactivity genes enriched in the A1 (LPS-treatment), A2 (MCAO ischemia) and pan-reactive phenotypes, or related controls (saline and sham, respectively). (c) IL-6 secretion from pAstrocytes (cerebral cortex, midbrain, cerebellum and whole brain (mixed regions)), and negative controls (fibroblasts and NPCs), after 24-hour treatment with 50 ng/ml or 100 ng/ml of Poly(I:C), 10 ng/ml or 50ng/ml of LPS, or 5 µM or 10 µM of Aβ42 and vehicle controls (saline for Poly(I:C) and LPS and Tris-HCl (pH 8) for Aβ ), as measured by ELISA. (d) IL-6 secretion following 24-hour treatment with Poly(I:C), LPS and Aβ42 across hiPSCastrocyte differentiations from 9 NPC lines from three independent hiPSC cohorts. hiPSC-Astros: hiPSC-astrocytes, pAstros: primary human fetal astrocytes. Data are represented as mean ± standard deviation. One-way ANOVA with Tukey multiple comparison test, * p < 0.05, ** p < 0.01, *** p < 0.001. The 11 screened conditions of astrocyte differentiation from hiPSCs, including 3 commercially available astrocyte media (#2-4) and 8 conditions modified from published protocols (#5-12), with a forebrain neuron differentiation protocol (#1). NEAA, non-essential amino acid, βME, 2-mercaptoethanol, AA, ascorbic acid, ND, non-disclosure, AM, astrocyte medium, AGS, astrocyte growth supplement. 
